UOC
ANTH

UBS O'Connor’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

UBS O'Connor’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-11,130
Closed -$398K – 963
2015
Q1 		$398K Buy
+11,130
New +$329K 0.01% 548
2013
Q4 		– Sell
-9,063
Closed -$291K – 530
2013
Q3 		$291K Sell
9,063
-312
-3% -$9.68K 0.01% 347
2013
Q2 		$278K Buy
+9,375
New +$350K 0.01% 446

Other funds holding ANTH

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

UBS O'Connor's ANTH Position: Q2 2015 in Review

UBS O'Connor sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2015, closing a stake of 11,130 shares — an estimated $398K sold.

UBS O'Connor first reported a position in ANTH in Q2 2013 and held it in 3 quarters. The position peaked at $398K in Q1 2015. 73 funds tracked by Wall St. Rank hold ANTH as of Q2 2015.

  • UBS O'Connor reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • UBS O'Connor sold 11,130 Anthera Pharmaceuticals, Inc. shares in Q2 2015, an estimated $398K.
  • UBS O'Connor first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2013 and held it in 3 quarters.
  • UBS O'Connor's Anthera Pharmaceuticals, Inc. position peaked at $398K in Q1 2015.
  • 73 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2015.

Based on UBS O'Connor's 13F filing for Q2 2015, filed 13 Aug 2015.